Last reviewed 2026-05-18 · How we verify

ANC-501

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. · Phase 2 active Small molecule Quality 10/100

ANC-501 is a Small molecule drug developed by Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.. It is currently in Phase 2 development.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ANC-501
Sponsor	Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

ANC-501 in the Treatment of Adults With Major Depressive Disorder (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ANC-501 CI brief — competitive landscape report
ANC-501 updates RSS · CI watch RSS
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. portfolio CI

Frequently asked questions about ANC-501

What is ANC-501?

ANC-501 is a Small molecule drug developed by Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc..

Who makes ANC-501?

ANC-501 is developed by Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. (see full Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. pipeline at /company/ancora-bio-inc-d-b-a-embarkneuro-inc).

What development phase is ANC-501 in?

ANC-501 is in Phase 2.

Manufacturer: Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing